MaxCyte Q4 rev. $6.6-6.7mln, FY22 rev. $29.5-29.6mln, cash $155.6mln.

lunes, 12 de enero de 2026, 8:10 am ET1 min de lectura
MXCT--

• MaxCyte reports Q4 core revenue of $6.6-6.7mln, full-year revenue of $29.5-29.6mln. • SPL program-related revenue expected to be $0.4-0.6mln in Q4, $3.3-3.5mln for full year. • Total cash, cash equivalents, and investments at $155.6mln as of Dec 31, 2025.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios